Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2018 Oct;5(5):956-959.
doi: 10.1002/ehf2.12338. Epub 2018 Jul 24.

Sacubitril-valsartan in heart failure and multimorbidity patients

Raquel Rodil Fraile  1 , Vincenzo Malafarina  2   3 , Gregorio Tiberio López  1
Affiliations
Observational Study

Sacubitril-valsartan in heart failure and multimorbidity patients

Raquel Rodil Fraile et al. ESC Heart Fail. 2018 Oct.

Abstract

Aims: The poor control of symptoms in patients with advanced heart failure with reduced ejection function (HFrEF) can limit the functionality of patients. Sacubitril-valsartan, compared with enalapril, has been shown to reduce mortality and hospitalization, and nowadays, there is still little evidence about the improvement on functionality. The aim of our study is to analyse the improvement of the functional class and the 6 min walking test (6MWT) in patients with multiple pathologies and advanced heart failure.

Methods and results: From September 2016 to March 2018, 65 multimorbidity patients with severe symptomatic HFrEF were initiated to receive sacubitril-valsartan. Mean age was 78.6 ± 7.4 years, and 68% were male. The Charlson co-morbidity index was 8 points. Seventy-four per cent had New York Heart Association (NYHA) Functional Class IV. After the treatment, patients were able to achieve 55.68 m or more on 6MWT, and 91% presented an improvement in the NYHA functional class.

Conclusions: Sacubitril-valsartan relieves symptoms and improves functional class prognostic risk of patients with advanced HFrEF and co-morbidity.

Keywords: Elderly; MAGGIC score; Multimorbidity; NYHA; Sacubitril-valsartan; Six-minute walking test.

PubMed Disclaimer

Comment in

References

    1. Anderson G. Chronic Care: Making the Case for Ongoing Care. Princeton, NJ: Robert Wood Foundation; 2010.
    1. Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo‐Leiro MG, Harjola VP. Epidemiology and one‐year outcomes in patients with chronic heart failure and preserved, mid‐range and reduced ejection fraction: an analysis of the ESC Heart Failure Long‐Term Registry. Eur J Heart Fail 2017; 19: 1574–1585. - PubMed
    1. Chamberlain AM, St Sauver JL, Gerber Y, Manemann SM, Boyd CM, Dunlay SM, Rocca WA, Finney Rutten LJ, Jiang R, Weston SA, Roger VL. Multimorbidity in heart failure: a community perspective. Am J Med 2015; 128: 38–45. - PMC - PubMed
    1. Manemann SM, Chamberlain AM, Boyd CM, Gerber Y, Dunlay SM, Weston SA, Jiang R, Roger VL. Multimorbidity in heart failure: impact on outcomes. J Am Geriatr Soc 2016; 64: 1469–1474. - PMC - PubMed
    1. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM‐HF Investigators and Committees . Angiotensin‐neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993–1004. - PubMed

Publication types

LinkOut - more resources